Back to journals
Academic JournalOpen Access

Frontiers in Psychiatry

80 Papers Indexed in Blossom

Published Papers

Open Accessindividual

Synergies in psychedelic-assisted therapy: a qualitative interview study of psychotherapeutic processes

This qualitative study (n=7) interviewed Swiss therapists about psychedelic-assisted therapy and found they saw psychedelics as working alongside psychotherapy rather than replacing it. Therapists described a synergy that could strengthen trust, depth and meaningful therapeutic experiences within long-term treatment.

Published
Journal
Frontiers in Psychiatry
Authors
Stellmacher, J., Schmidt, C., Aicher, H. D., Eichel, K., Brakemeier, E. L., Herwig, U.
Open Accessindividual

Acute and post-dosing effects of single-dose psilocybin for obsessive-compulsive disorder in a randomized, double-blind, placebo-controlled trial: an interpretative phenomenological analysis

Qualitative interviews with 12 participants from a randomized, placebo‑controlled single‑dose psilocybin trial for treatment‑refractory OCD showed that set and setting strongly shaped acute (often partial) perceptual, emotional and metacognitive experiences, which were followed by post‑dosing changes in OCD symptoms, perceptions and behavioural/metacognitive processes. These changes mapped onto putative mechanisms of ERP and ACT, suggesting hypotheses for further study and potential value in integrating psilocybin with structured psychotherapy for OCD.

Published
Journal
Frontiers in Psychiatry
Authors
Ching, T. H. W., Stahnke, B., Shnayder, S., Agin-Liebes, G., Adams, T. G., Amoroso, L., Baiz, O., Belser, A., Bohner, C., Burke, M., D’Amico, E., DePalmer, G., Eilbott, J., Fram, G., Grazioplene, R., Hokanson, J., Jankovsky, A., Kichuk, S. A., Martins, B., Purohit, P., Schaer, H., Sierra, Y. P., Witherow, C., Pittenger, C., Kelmendi, B.
Open Accessindividual

DMT and harmala alkaloids: an exploratory study of oral Acacia based formulations in healthy volunteers

In this open-label exploratory crossover study of nine experienced ayahuasca users, three Acacia‑derived oral formulations delivering DMT plus harmala alkaloids were well tolerated, produced no clinically significant physiological changes, and elicited psychedelic effects rated comparable to (and for ACL‑010 sometimes more beneficial than) traditional ayahuasca. These findings suggest Acacia‑based DMT/harmala formulations are a feasible alternative for future clinical trials, although generalisability is limited by the small sample size and open‑label design.

Published
Journal
Frontiers in Psychiatry
Authors
Bonomo, Y. A., Norman, A. F., Collins, L., Ross, M., Dwyer, J., Perkins, D., Sarris, J.
Open Accessindividual

Improved mental health outcomes and normalised spontaneous EEG activity in veterans reporting a history of traumatic brain injuries following participation in a psilocybin retreat

In a preliminary uncontrolled study of 21 veterans with traumatic brain injury, participation in two psilocybin retreat ceremonies was associated with large reductions in PTSD, depression and anxiety symptoms and with EEG changes (reduced frontal/temporal delta–theta power and increased alpha–beta coherence) consistent with improved emotional regulation and neural communication. These findings suggest psilocybin retreats may improve psychological wellbeing and brain connectivity in veterans with TBI and warrant larger, controlled trials.

Published
Journal
Frontiers in Psychiatry
Authors
Blest-Hopley, G., Pasculli, G., Ruffell, S. G. D., Tsang, WF., Emmanuel, O., Pate, K. M., Kettner, H., Roseman, L., Erritzoe, D., Carhart-Harris, R. L.
Open Accessmeta

Hype or hope? High placebo response in major depression treatment with ketamine and esketamine: a systematic review and meta-analysis

This meta-analysis of 14 RCTs (1,100 participants) found large antidepressant effects for ketamine and esketamine. However, the pooled placebo response accounted for up to 72% of the overall treatment effect (66% at seven days), indicating a major contribution of placebo to observed benefits and implications for clinical practice.

Published
Journal
Frontiers in Psychiatry
Authors
Matsingos, A., Wilhelm, M., Noor, L., Yildiz, C., Rief, W., Hofmann, S. G., Falkenberg, I., Kircher, T., Eugene, A. R., Yang, J. J.
Open Accessindividual

Safety, tolerability, pharmacodynamic and wellbeing effects of SPL026 (dimethyltryptamine fumarate) in healthy participants: a randomized, placebo-controlled phase 1 trial

In a randomized, placebo‑controlled Phase 1 trial in psychedelic‑naïve healthy volunteers, single escalating IV doses of SPL026 (DMT fumarate) were well tolerated with an acceptable safety profile and showed dose‑related increases in acute psychometric intensity that correlated with plasma concentrations; based on safety, PK and pharmacodynamic data a 21.5 mg two‑phase 10‑minute infusion was selected for the subsequent Phase 2a study.

Published
Journal
Frontiers in Psychiatry
Authors
James, E., Erritzoe, D., Benway, T., Joel, Z., Timmermann, C., Good, M., Agnorelli, C., Weiss, B., Barba, T., Campbell, G., Jones, M., Hughes, C., Topping, H., Boyce, M., Routledge, C.

Quick Facts

Papers Indexed
80
h-Index
134
Open Access
Yes
Publisher
Frontiers Media
Country
Switzerland
Website
Visit